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 Asthma treatments have been remarkably successful 
at controlling symptoms. Up to 75% of people 
with asthma can achieve adequate asthma contrai 
on inhaled corticosteroids (ICS) with or without 
long-acting �2-agonists (LABA).1 But real-life studies 
have been sobering, indicating that full asthma 
control is only attained in about 30-40% of people 
with asthma.2 Many patients retain impairment of 
lung function and poor quality of life.3 
Suboptimal asthma contrai might occur for various 
reasons, but there is consensus that poor adherence 
with asthma medications is a cardinal cause.3 Studies 
have suggested that asthmatics are especially prone to 
lapse treatment during asymptomatic periods when 
having to take regular treatment interferes with their 
lifestyle. Patients also have concerns about long­
term side-effects of ICS, and many choose to live with 
persistent asthma symptoms. Finally, since asthma is a 
disease characterised by chronic airway inflammation 
with variable airflow limitation and unpredictable 
symptoms, treatment often requires frequent adjust­
ment to achieve total contrai of chronic asthma. 
This aim might only be possible to attain in a small 
proportion of patients. 
lmproving adherence to asthma medication has 
proven difficult, despite educational strategies such 
as asthma management plans and simplified inhaler 
devices.3 For example, despite comprehensive edu­
cational asthma programmes targeting patients 
and general practitioners in countries like Australia, 
rates of adherence remain poor. There have also 
been schemes to educate patients about the long­
term safety of ICS, but there remains considerable 
so-called corticophobia in the general population, 
and this is unlikely to change. Recognition of the key 
role of adherence has prompted novel approaches 
in other diseases. Introduction of directly-observed­
therapy (DOT) in tuberculosis has resulted in improved 
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adherence with matching gains in cure rates.4 Whether 
this approach is applicable to asthma should perhaps 
be considered. 
lt can be argued that our current treatment para­
digms for asthma are theoretical constructs that fail, 
at least in part, at a practical level. However, recent 
innovations might permit an alternative approach. 
First, asthma management has been improved by the 
implementation of maintenance and reliever therapy 
(MART) by use of an ICS-LABA combined inhaler. 
Patients are encouraged to use regular ICS and LABA 
but to augment inhaled treatment immediately 
when asthma symptoms flare. The strategy has been 
shown to reduce asthma exacerbations and lessen 
overall corticosteroid exposure.5 A recent non-industry 
funded, controlled study6 confirmed that MART had 
projected benefits on asthma exacerbations and 
corticosteroid exposure. MART has gradually gained 
acceptance worldwide as a feasible and working 
therapeutic option for asthma.7 
A second important aspect is the successful 
development of biological drugs to optimally treat 
patients with severe asthma on the basis of disease 
phenotyping and biomarkers. Monoclonal antibody 
treatments such as anti-lgE, and more recently anti­
lL-5, anti-lL-4, and anti-lL-138 have shown their 
ability to treat so-called T2-related asthma. These 
studies have shown reductions in exacerbations 
and some improvements in lung function, asthma 
control, and quality-of-life outcomes. Most of the 
asthma population might be eligible for this kind of 
intervention. lmportantly, these treatments can be 
administered at monthly intervals (or possibly longer) 
via subcutaneous injection and have minimal side­
effects. They are therefore potentially suitable for 
strategies that implement DOT to improve adherence 
and disease contrai in asthma. 
We therefore propose a new treatment paradigm 
for asthma. This approach has four steps (figure). 
First, people with asthma who are likely to respond to 
modulation of lgE, IL-5, IL-4, or IL-13 are identified. 
Second, daily ICS-LABA is replaced by biological 
therapy every month or every 2 months given as DOT. 
The patient's general practitioner can do this step 
and establish the optimal rhythm of injection. Third, 
patients are educated to use ICS-LABA or long-acting 
muscarinic-antagonists (LAMA) on an as-needed 
basis (MART) for flares of asthma symptoms. Finally, 
patients are monitored to ensure asthma control is 
maintained. 
Could this overhaul of current asthma approaches 
work? Several lines of evidence suggest that it might 
improve current practice. The use of MART strategies 
has gained wide acceptance and although DOT has 
chiefly been used in tuberculosis, it appears suitable 
for application in a chronic disease such as asthma. 
Biological therapies have been effective and several 
compounds have shown efficacy with a reasonable 
safety profile. Finally, an analogous therapeutic 
approach using pre-seasonal omalizumab injections in 
children has been successful.9 
However, there are important caveats. Substantial 
clinical research will be required to examine the 
effectiveness and feasibility of the proposai. Strategies 
to combine randomised studies with real-life 
pragmatic studies, not only in severe asthma but also 
in mild asthma, will be essential. Studies will also 
be needed to validate the overall strategy; examine 
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ICS), and refers to the y axis, treatment pressure. During the total contrai phase, ICS dose is halved. Patients are 
then allowed to stop their regular, daily use of inhaled asthma medications ("triple", which means association of 
ICS, LABA and LAMA in the same device) once total asthma contrai is achieved thanks to the mAb injections 
(controller triple withdrawal). These inhalers will be kept only for treating /lare up, as a symptom reliever, 
on demand. Du ring the flare-up phase, the daily dose of ICS in inhaled therapies increases. For both the blue and 
red line, dashes indicate that the length of time in which asthma symptoms are totally controlled is undetermined. 
mAb=monoclonal antibody. ICS=inhaled corticosteroids. LABA=long-acting �2-agonists. LAMA=long-acting 
muscarinic-antagonists. 
asthma outcomes, costs, and viability; identify 
patients with a treatable trait who will beneiït;10 and 
substantiate acceptability to populations with asthma. 
The potential benefits of reversing asthma treat­
ment paradigms are evident: improved adherence, 
enhanced asthma control, fewer side-effects from ICS­
LABA medications, simplified asthma management 
and greater convenience for patients. lndeed, 
regular anti-inflammatory treatment with biological 
therapies has the potential to reduce overall asthma 
severity. Since safety concerns have been satisfactorily 
addressed, cost considerations are likely to be the 
major limitation to their use. If this issue can be 
mitigated a reversai of current treatment algorithms 
might have substantial benefits and improve asthma 
management. 
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